Full Text Available

Note: Clicking the button above will open the full text document at the original institutional repository in a new window.

Development of a constitutive luciferase reporter line for comparable evaluation of antiplasmodial drugs on all life cycle stages of Plasmodium falciparum

Dissertation (MSc (Biotechnology))--University of Pretoria, 2020.

Saved in:
Bibliographic Details
Other Authors: Birkholtz, Lyn-Marie
Format: Thesis
Language:English
Published: University of Pretoria 2022
Subjects:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1867613480069103616
access_status_str Open Access
author2 Birkholtz, Lyn-Marie
author_browse Birkholtz, Lyn-Marie
author_facet Birkholtz, Lyn-Marie
collection Thesis
dc_rights_str_mv © 2021 University of Pretoria. All rights reserved. The copyright in this work vests in the University of Pretoria. No part of this work may be reproduced or transmitted in any form or by any means, without the prior written permission of the University of Pretoria.
description Dissertation (MSc (Biotechnology))--University of Pretoria, 2020.
format Thesis
id oai:repository.up.ac.za:2263/83244
institution University of Pretoria (South Africa)
language English
last_indexed 2026-06-10T12:36:48.836Z
license_str Other — see source repository
provenance_str_mv Harvested via OAI-PMH from UPSpace — University of Pretoria Institutional Repository
publishDate 2022
publishDateRange 2022
publishDateSort 2022
publisher University of Pretoria
publisherStr University of Pretoria
record_format dspace
source_str UPSpace — University of Pretoria Institutional Repository
spelling oai:repository.up.ac.za:2263/83244 Development of a constitutive luciferase reporter line for comparable evaluation of antiplasmodial drugs on all life cycle stages of Plasmodium falciparum Birkholtz, Lyn-Marie u13413628@tuks.co.za Joubert, Dorè UCTD Dissertation (MSc (Biotechnology))--University of Pretoria, 2020. The vision of a malaria-free world is threatened by antimalarial drug resistance. For malaria elimination to be achieved, drug combinations should have dual action: cure infection and block transmission of the Plasmodium parasite between the human host and mosquito vector. Furthermore, such dual action drugs should lower the risk of resistance development and prolong the therapeutic lifespan of antimalarials. New antimalarial drugs need to comply to a set guideline from the Medicines for Malaria Venture with regards to the types of molecules [target candidate profiles (TCP)] and the combination of medicines being developed. Therefore, knowing a compound’s activity towards a specific stage of the parasite, in other words its TCP, is important for drug development. However, due to the parasite’s complex life cycle, each stage of the parasite currently requires a different biochemical platform to assay compounds for activity against that particular life cycle state. This does introduce assay readout variability and complicates standardisation of drug assays. This study, therefore, aimed to generate a constitutive luciferase-expressing P. falciparum line that can be used to develop a single assay platform for all life cycle stages of the parasite. By using gene expression profiling, we identified several constitutively expressed genes throughout the life cycle of P. falciparum. The promoters of these genes were used to generate transgenic lines in which a robust luciferase reporter is strongly expressed under control of these promoters. Two transgenic lines were successfully generated and allowed luciferase expression under control of promoters for histone H3 and nuclear assembly protein (NF54H3 and NF54nap). Whilst NF54H3 could be used to effectively determine antiplasmodial activity for compounds towards the asexual stages, this line was compromised to the extent that it was not able to produce gametocytes. By contrast, NF54nap produced both asexual parasites and gametocytes and was used to evaluate drug activity for both these stages on a single luciferase reporter assay platform. As a result, the line generated here enables a single platform to delineate the TCP of compounds and identify novel compounds that are active against multiple stages or that show selective activity towards a specific stage of the parasite. This data contributes to a novel avenue in antimalarial drug discovery, thereby supporting malaria elimination strategies. Biochemistry MSc (Biotechnology) Unrestricted 2022-01-12T06:00:47Z 2022-01-12T06:00:47Z 2021/05/05 2020 Dissertation * A2021 http://hdl.handle.net/2263/83244 en © 2021 University of Pretoria. All rights reserved. The copyright in this work vests in the University of Pretoria. No part of this work may be reproduced or transmitted in any form or by any means, without the prior written permission of the University of Pretoria. application/pdf University of Pretoria
spellingShingle UCTD
Development of a constitutive luciferase reporter line for comparable evaluation of antiplasmodial drugs on all life cycle stages of Plasmodium falciparum
title Development of a constitutive luciferase reporter line for comparable evaluation of antiplasmodial drugs on all life cycle stages of Plasmodium falciparum
title_full Development of a constitutive luciferase reporter line for comparable evaluation of antiplasmodial drugs on all life cycle stages of Plasmodium falciparum
title_fullStr Development of a constitutive luciferase reporter line for comparable evaluation of antiplasmodial drugs on all life cycle stages of Plasmodium falciparum
title_full_unstemmed Development of a constitutive luciferase reporter line for comparable evaluation of antiplasmodial drugs on all life cycle stages of Plasmodium falciparum
title_short Development of a constitutive luciferase reporter line for comparable evaluation of antiplasmodial drugs on all life cycle stages of Plasmodium falciparum
title_sort development of a constitutive luciferase reporter line for comparable evaluation of antiplasmodial drugs on all life cycle stages of plasmodium falciparum
topic UCTD
url http://hdl.handle.net/2263/83244